SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 711.33+2.6%12:34 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (2325)5/3/2018 4:55:41 PM
From: Miljenko Zuanic1 Recommendation

Recommended By
DewDiligence_on_SI

  Read Replies (2) of 3559
 
Now we know it is for >50% PDL1 expression, where Keyt become SOC.
clinicaltrials.gov

Still do not understand what they want to achieve by combining 2810 with Ipi, when their own anti-CTLA4-ab (REGN4659, files.shareholder.com is way behind.

Also, no idea what dose/schedule for Ipi is in protocol, as well what is expectation???
In addition, from patent applications and animal study for in-house anti-CTLA-4 chombo, data are scarce.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News